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Background: Kabuki syndrome is a rare hereditary disease affecting multiple organs. The causative genes identified
to date are KMT2D and KDMA6. The aim of this study is to evaluate the clinical manifestations and the spectrum of
mutations of KMT2D.
Methods: We retrospectively retrieved a series of eight patients from two hospitals in China and conducted Sanger
sequencing for all of the patients and their parents if available. We also reviewed the literature and plotted the
mutation spectrum of KMT2D.
Results: The patients generally presented with typical clinical manifestations as previously reported in other
countries. Uncommon symptoms included spinal bifida and Dandy-Walker malformation. With respect to the
mutations, five mutations were found in five patients, including two frameshift indels, one nonsense mutation
and two missense mutations.
Conclusions: This is the first case series on Kabuki syndrome in Mainland China. Unusual symptoms, such as
spinal bifida and Dandy-Walker syndrome, suggested that neurological developmental defects may accompany
Kabuki syndrome. This case series helps broaden the mutation spectrum of Kabuki syndrome and adds information
regarding the manifestations of Kabuki syndrome.
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Kabuki syndrome or Kabuki make-up syndrome was
originally described in 1981 following observations of
five Japanese children whose conditions were characterized
by mental retardation, dwarfism and peculiar faces and
abnormal dermatoglyphics [1]. Historically, the diagnostic
criteria for Kabuki syndrome were mainly based on the
typical clinical manifestations, which were established
by analyzing a group of sixty-two patients with
Kabuki syndrome in 1988 [2]. Five cardinal manifes-
tations were frequently observed in patients with
Kabuki syndrome and could be used as diagnostic clues, in-
cluding peculiar facial appearances, mild-to-moderate
mental retardation, dermatoglyphic abnormalities, skeletal* Correspondence: xiongfw2013@163.com; zhengqingqiu33@aliyun.com
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unless otherwise stated.anomalies, and postnatal growth deficiencies. Kabuki
syndrome was previously considered to be prevalent
in only Japan, but it has now been recognized to be
prevalent all over the world. The estimated preva-
lence in Japan is approximately 1/32,000, whereas the
estimated prevalence is at least 1/86,000 in Australia
and New Zealand [2,3].
The underlying genetic mutation of Kabuki syndrome
was not revealed until the year 2010, when exome
sequencing identified MLL2 mutations in Kabuki
syndrome patients (Kabuki syndrome 1, OMIM 147920)
[4]. Bögershausen et al proposed a new nomenclature
for the MLL2 gene as KMT2D [5]. KMT2D consists of
fifty-four coding regions and functions as a histone-
lysine N-methyltransferase in various signalling pathways
such as epigenetic modulating. However, KMT2D
mutations alone were not able to account for all Kabuki
syndrome cases. Later, mutations in the KDM6A gene,
which encodes a histone demethylase that interacts
with KMT2D, were identified (Kabuki syndrome 2,s is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the KMT2D and KDM6A genes would help confirm the
diagnosis in patients who fulfilled the clinical diagnostic
criteria for Kabuki syndrome.
Medical centres and institutions in Europe, North
America and South America have carried out extensive
KMT2D mutation spectrum reports. However, studies
concerning the KMT2D mutation spectrum in China
have rarely been reported. This study describes the first
case series of eight Chinese patients with Kabuki syn-
drome, their clinical manifestations, and their atypical
symptoms. We also analyzed the genetic changes in the
KMT2D gene and conducted a literature review of the
KMT2D mutation spectrum. The main aim of this study
was to determine the mutation spectrum of the KMT2D
gene in Chinese Kabuki patients and to review the muta-
tion spectrum reported in the literature.
Methods
Patients
This study was reviewed and approved by the Peking
Union Medical Collage Hospital Ethics Review Board.
All of the participants’ legal guardians provided their
written informed consents to participate on behalf of the
children and/or for themselves. We obtained written in-
formed consent to publish characteristic features of the
disease and to maximally hide other non-disease-related
features, thus protecting the privacy for each patient.
We retrospectively searched the clinical records for
the initial outpatient visit covering from January 2010 to
February 2013 in the Department of Pediatrics, Peking
Union Medical College Hospital (PUMCH), Beijing,
China and Children’s Hospital of ChongQing Medical
University (CH-CQMU), ChongQing, China. Those
patients with a clinical diagnosis of “Kabuki syndrome”
were enrolled. Overall, eight patients were enrolled.
Clinical manifestations were retrieved from the original
clinical records. A telephone-based follow-up was con-
ducted to ask for patients’ current height and weight as
of February 2013.
Sanger sequencing of KMT2D gene and identification of
pathogenic mutations
KMT2D gene mutation status was obtained by Sanger
sequencing after obtaining informed consent. First,
peripheral blood samples from each patient were
collected. Blood samples from the parents were also
collected if available. Then, the total genomic DNA was
extracted by standard procedures, and the 54 exons and
exon-intron junctions of the KMT2D gene (UCSC
NM_003482) were amplified in three PCR fragments.
Exons were amplified in a reaction containing 2 μL of
10x PCR buffer, 3 μL of dNTPs (2.5 mmol/L), 0.3 μL of
rTaq polymerase (5 U/μL) (TAKARA, Dalian, China),1 μL of genomic DNA (100 ng/μL), 1 μL of each primer
(10 pmol/μL), and 11.7 μL of ddH2O. The thermal cycler
conditions were as follows: 95°C for 5 min, then 35 cycles
of 94°C for 30 s, 59°C for 30 s, and 72°C for 45 s, and a
final elongation step at 72°C for 5 min. Direct sequencing
was performed on a Genetic Analyzer (Biomed Corp,
Beijing, China). As a reference, the A of the ATG transla-
tion initiation codon of coding sequence of KMT2D was
referred to as nucleotide +1.
Results from Sanger sequencing were compared with
the reference sequence of KMT2D to identify single
nucleotide substitutions, frameshift indels, and non-
frameshift indels. Novel missense mutations would be
subjected to further analysis to explore their pathogen-
icity. First, the parents’ KMT2D genes were sequenced.
Second, the proband’s missense mutation was searched
in the 1000 Genomes Database and in the Exome
Variant Server [7]. Finally, the pathogenicity of protein
change due to the missense mutation was predicted
using the in silico prediction models SIFT, PROVEAN
and Polyphen-2 [8,9].
Literature review of the KMT2D gene mutation spectrum
Two of the authors (CS and XH) independently searched
the published literature in MEDLINE and EMBASE
using the following search keys: (“Kabuki syndrome” OR
“Kabuki make-up syndrome” OR “Niikawa-Kuroki
syndrome”) AND (“KMT2D” OR “MLL2”), without
language restriction, with published data up to January
6, 2015. Another author (ZQ) supervised the literature
review process and resolved any disagreement between
the authors (CS and XH) regarding a study’s inclusion.
Articles were manually reviewed, and KMT2D mutation
data were retrieved. Here, we included only studies with
10 or more patients. The KMT2D mutations were
summarized and categorized as “missense,” “frameshift
indel” or “nonsense.”
Results
Clinical manifestations of eight Chinese patients with
Kabuki syndrome
We identified eight patients with a clinical diagnosis of
Kabuki syndrome (six from PUMCH and two from CH-
CQMU). Six patients were male, and two were female.
The ages of initial diagnosis ranged from 8 months to
9 years. All of patients belonged to the Han ethnic group.
The general clinical manifestations were categorized in
a “five cardinal manifestations” pattern, which included
typical craniofacial abnormalities, skeletal abnormalities,
dermatoglyphic abnormalities, cerebral abnormalities,
and postnatal growth deficiencies (Table 1). The percent-
ages of patients with each symptom were compared with
previous reports [10]. The typical features of the
aforementioned patients are illustrated in Figure 1.
Table 1 Clinical manifestations of eight patients with Kabuki syndrome




General Information Gender M M F M F M M M
Age of diagnosis 7 y 3 y 8 y 8 mo 2 y 9 y 4 y 11 m 4 y 1 m
Age at follow-up 8 y 4 y 3 y 5 y 6 m
Typical craniofacial abnormality High/sparse eyebrows + + + + + + + + 100.0% 85%
Long palpebral fissures + + + + + + + + 100.0% 99%
Blue sclera - + + + + - + 71.4% 31%
Strabismus - - - - - - + - 12.5% 36%
Ptosis - - - - - - - - 0.0% 50%
Large ears + + + + + + + + 100.0% 84%
Depressed nasal tip + + + + + + + + 100.0% 83%
Micrognathia - + - + + + 66.7% 40%
Abnormal dentition - - + + 50.0% 68%
skeletal abnormality Clinodactyly of the 5th finger + + - + - - - + 50.0% 50%
Hip dislocation + - - - - - - 14.3% 18%
Hyperlaxity + - - - - - + 28.6% 74%
Scoliosis/vertebral malformation + - - - - - - - 12.5% 32%
Dermatoglyphic abnormalities Fingertip pads + + + + + + + + 100.0% 89%
Cerebral abnormality Mental retardation + + + + + + - + 87.5% 84%
Hypotonia - - - - - - - + 12.5% 68%
Seizures - - + - + - - - 25% 17%
Head circumference at initial
outpatient diagnosis (cm)
51 46.7 50 42.5 42 49.8 49 46.7
Microcephaly - - - - + - - + 25% 26%
Postnatal growth Weight at birth (g) 3250 2500 2650 2950 2000
Body length at birth (cm) 50 48 49
Weight at initial outpatient diagnosis (kg) 26 13 7 20 14 11
Height at initial outpatient diagnosis (cm) 121 101 107 99 86
Weight at follow-up (kg) 27 15 12
Height at follow-up (cm) 125 102 96 98
Postnatal growth retardation - - - + + - 33.3% 55%













Table 1 Clinical manifestations of eight patients with Kabuki syndrome (Continued)
Other common symptoms Frequent infections + + - - + - + + 62.5% 60%
Cardiac anomalies - - - - + - + + 37.5% 42%













Figure 1 Typical patient abnormalitie. (A) High/sparse eyebrows by
Patient 2. (B) High/sparse eyebrows demonstrated by Patient 3.
(C) Depressed nasal tip demonstrated by Patient 5. (D) Depressed
nasal tip demonstrated by Patient 8. (E) Hyperlaxity demonstrated by
Patient 8. (F) Fingertip pads demonstrated by Patient 8.
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typical craniofacial abnormalities, including high/sparse
eyebrows, long palpebral fissures with eversion of the
lateral third of the lower eyelids, large ears and de-
pressed nasal tips and blue sclera. The percentages of
patients presenting with strabismus and ptosis were
lower than in previous reports.
With respect to skeletal abnormalities, four patients
presented with clinodactyly of the 5th finger. Patient 1
was diagnosed with bilateral hip dislocation at one year
of age and underwent corrective surgery. The same pa-
tient also presented with hyperlaxity and spina bifida
occulta. Patient 8 also presented with hyperlaxity.
All of the patients presented with fingertip pads typical
of previously reported dermatoglyphic abnormalities.
With respect to cerebral abnormalities, seven out of
the eight patients presented with mental retardation.
Only Patient 5 and Patient 8 presented with micro-
cephaly (two standard deviations from the median
value) according to the standard for Chinese children
[11]. With respect to seizures, Patient 5 and Patient
3 exhibited this manifestation. Patient 5 presented
with an episode of seizure that occurred in the first
day of life and was infantile spasm type. MRI indi-
cated corpus callosum hypoplasia and Dandy-Walker
malformation, which indicated that congenital cerebral
developmental defects might happen concomitantly with
Kabuki syndrome.
With respect to postnatal growth, Patient 6 and
Patient 7 were diagnosed with postnatal growth re-
tardation, and Patient 1 experienced self-reported feeding
difficulties.In addition to these five cardinal manifestations,
Patient 1 experienced fever or diarrhoea every other
week from the age of two to three. Patient 2 experienced
multiple upper respiratory symptoms and tonsillitis when
he was 3 years old. Patients 5, 7 and 8 experienced frequent
respiratory infections. With respect to cardiac abnormal-
ities, Patient 5 was diagnosed with a patent foramen ovale
and Patient 7 and Patient 8 presented with atrial septal
defects. Patient 2 presented with pectus carinatum, and
Patient 3 presented with bilateral knee joint stiffness.
Review of the KMT2D gene mutation spectrum in Kabuki
syndrome
We performed a literature review of the published stud-
ies on KMT2D gene mutations based upon the method
described above. The number of studies from MEDLINE
and EMBASE were 48 and 182, respectively. After mer-
ging the duplicates, there were 201 published articles.
Each abstract was manually read, and data were
retrieved if available. The data from the included studies
contributed to the further analysis.
Briefly, we included 12 studies for further analysis
[4,12-22] to compare the distribution of the previously
reported KMT2D gene mutations with our case series.
We first summarized the different types of mutations
from these studies.
There were 146 (47%) frameshift indels, 105 (34%)
nonsense mutations, and 56 (18%) pathogenic missense
mutations (Figure 2). We did not include splice-site and
in-frame indels because the pathogenicity of these muta-
tions would require specific investigation. Mutation hot-
spots were identified in exons 10, 31, 34, 39, and 48.
Sanger sequencing to identify mutations in the KMT2D
gene in this study
Our eight patients underwent genetic analysis of the
KMT2D gene, and ten variants were detected (Table 2).
Unlike the distribution in previous reports, only two
frameshift indels and one nonsense mutation were iden-
tified, which were c.3095delT in Patient 4, c.4395dupC
in Patient 6 and c.4140T > A in Patient 8. One in-frame
indel, c.11718-11723delGCAACA, was also identified in
Patient 8. Six missense variants were also identified.
Patient 1 had two missense variants, c.12199C > T
and c.16295G > A (Figure 3). Patients 2, 3, 5 and 7
had one missense variant each: c.4664C > T, c.8639T > C,
c.96C > G (p.Asp32Glu) and c.11638C > A, respectively.
We sequenced both of the parents of Patients 1, 2, 3 and 5
and found none of the previously described missense vari-
ants in the parents’ KMT2D genes. The other four patients’
parents were not available for genetic testing.
We did not find any of the missense variants identified
in this series in the 1000 Genomes Database or the
Exome Variant Server.
Figure 2 Mutation spectrum of the KMT2D gene. (A) Schematic view of the KMT2D gene. Each note above represents a variant in this case series
(a red note indicates a pathogenic mutation). Each type of mutation is illustrated as a dot with a distinct combination of colour and shape. Each
dot below represents a genetic mutation reported in the literature. (B) Schematic view of the number and proportion of missense, nonsense and
in-frame indel mutations in the KMT2D gene.
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the in silico prediction models SIFT, PROVEAN and
Polyphen-2 to predict the protein changes due to the
missense variants. Two missense variants (c.16295G > A
and c.8639T > C) were predicted to be pathogenic by all
three of the models. Therefore, we categorized those two
variants as “pathogenicity confirmed.” However, the
other four missense variants (c.12199C > T, c.4664C > T,
c.96C > G and c.11638C > A) were predicted to be be-
nign, neutral or tolerable by at least two of the pro-
grams. Therefore, we would categorize those four
variants as “pathogenicity undetermined.” The single in-
frame indel in Patient 8 (c.11718-11723delGCAACA)
was also categorized as “pathogenicity undetermined.”
In conclusion, five of the eight patients had pathogenic
mutations in the KMT2D gene. These patients were
Patient 1 (c.16295G > A), Patient 3 (c.8639T > C),
Patient 4 (c.3095delT), Patient 6 (c.4395dupC), and
Patient 8 (c.4140T > A). Three of the eight patients did
not have confirmatory pathogenic mutations in the
KMT2D gene, and the clinical symptoms could not be
ascribed to KMT2D gene mutations. These patients were
Patient 2, Patient 5, and Patient 7.
Nine of the ten variants were novel. One missense
variant (c.16295G > A) was previously reported by
Kokitsu-Nakata et al [23].Discussion
Kabuki syndrome is a rare congenital disease. Cases
from different parts of the world have been extensively
reported. However, reports on Chinese patients with
Kabuki syndrome have been rare. To our knowledge, five
cases of Chinese patients due to this disease were pub-
lished in several case reports [24-27]. However, the
KMT2D mutation status was not available for these
cases. This is the first case series to include both the typ-
ical clinical manifestations and the KMT2D mutation
status of patients from Mainland China. The clinical
manifestations in this case series were consistent with
the clinical diagnostic criteria.
With respect to atypical symptoms, Patient 5 pre-
sented with hypoplasia of the corpus callosum and
Dandy-Walker malformation. Increasing evidence sug-
gests that structural central nervous system (CNS) mal-
formations, including Dandy-Walker malformation, can
be present in Kabuki syndrome patients [28-31]. These
congenital neurologic defects may partially account for
the mental retardation commonly observed in Kabuki
syndrome patients. Further analysis is needed to evaluate
whether CNS structural defect are frequent in patients
with Kabuki syndrome.
With respect to congenital heart defects, the major
types associated with Kabuki syndrome are left-sided
Table 2 KMT2D gene variants analysis
Patient Mutation Type of mutation Predicted protein
changes
Inheritance Exon PROVEAN prediction SIFT prediction Polyphen-2 prediction Pathogenicity Novelty
Score Prediction* Score Prediction** Score Prediction
Patient 1 c.12199C > T Missense p.Pro4067Ser De novo 39 −1.663 Neutral 0 Damaging 0.085 Benign Undetermined Novel




Patient 2 c.4664C > T Missense p.Ser1555Phe De novo 17 −0.958 Neutral 0.682 Tolerated 0.976 Probably
damaging
Undetermined Novel
Patient 3 c.8639T > C Missense p.Leu2880Pro De novo 34 −5.055 Deleterious 0 Damaging 1.000 Probably
damaging
Confirmed Novel
Patient 4 c.3095delT Frameshift indel p.Leu1032Argfs24X N/A 11 Confirmed Novel
Patient 5 c.96C > G Missense p.Asp32Glu De novo 2 0.423 Neutral 0.106 Tolerated 0.001 Benign Undetermined Novel
Patient 6 c.4395dupC Frameshift indel p.Lys1466Glnfs25X N/A 15 Confirmed Novel
Patient 7 c.11638C > A Missense p.Leu3880Met N/A 39 0.500 Neutral 0.008 Damaging 0.003 Benign Undetermined Novel
Patient 8 c.4140T > A Nonsense p.Cys1370X N/A 14 Confirmed Novel
c.11718-11723delGCAACA Non-frameshift
indel















Figure 3 Sanger sequencing of Patient 1 with two de novo mutations. (A) The missense mutation c.12199C > T in Patient 1. (B, C) Both parents
had no mutations at c.12199. (D) The missense mutation c.16295G > A in Patient 1. (E, F) Both parents had no mutation at c. 16295.
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(COA), atrial septal defects (ASDs), ventral septal de-
fects (VSDs), and tetralogy of Fallot (TOF), among
others [32,33]. In our series, two patients presented with
ASDs. Thus, we propose that patients should be meticu-
lously screened for congenital heart defects once the
diagnosis of Kabuki syndrome has been made.
Gene sequencing of KMT2D and KDM6A can be used
to detect mutations in patients with a clinical diagnosis
of Kabuki syndrome. Studies with large cohorts of
patients indicate that KMT2D gene mutations can be
detected in half to three-fourths of patients with clinical
diagnoses of Kabuki syndrome [13,16,17]. Pathogenic
KDM6A gene mutations account for a small percentage
of patients [14,16,19,34-36].
KMT2D pathogenic mutations were detected in five of
the eight patients in our case series. This case series
identified six missense variants, two frameshift indels,
one in-frame indel and one nonsense mutation. All of
the frameshift indels and nonsense mutations wereconsidered pathogenic because the protein structure was
significantly altered. However, we would urge caution in
interpreting the influence of missense mutations or in-
frame indels on protein function because some amino
acid substitutions would not necessarily impair protein
function. Therefore, we used in silico prediction models
to analyze the missense mutations and non-frameshift
indels.
We found two patients with two variants in their
KMT2D genes. Patient 1 had two missense mutations
(c.12199C > T and c.16295G > A), which were both ab-
sent from the parents’ KMT2D genes, indicating that
they were de novo mutations. Both mutations were ab-
sent from the 1000 Genomes Database and the Exome
Variant Server, indicating that both mutations are rare in
the general population. One mutation, c.12199C > T,
was predicted to be pathogenic by the SIFT program
but not by PROVEAN or Polyphen-2. The other mu-
tation, c.16295G > A, was predicted to be pathogenic
by all three in silico models and has been reported
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Kabuki syndrome [23]. Therefore, we considered
c.16295G > A to be pathogenic, whereas the patho-
genicity of c.12199C > T was inconclusive and could
potentially be non-pathogenic.
Patient 8 also had two variants. We could not deter-
mine the inheritance status because the parents of
Patient 8 refused to give blood samples for sequencing
of the KMT2D gene. One mutation was a nonsense
mutation (c.4140T > A), which was considered to be
pathogenic. The other mutation in this patient was an
in-frame deletion (c.11718-11723delGCAACA), which
was predicted to be non-pathogenic by the PROVEAN
prediction model. Therefore, the pathogenicity of c.11718-
11723delGCAACA was inconclusive and could potentially
be non-pathogenic. To our knowledge, it is a rare event for
a patient to carry two mutant variants of the KMT2D gene.
A previous study by Hannibal et al reported only three
patients who carried two KMT2D gene variants in a cohort
of 110 patients [22].
Conclusion
This report is the first case series of Kabuki syndrome
patients with definitive genetic diagnosis in China. These
data help broaden the mutation spectrum of Kabuki syn-
drome and add information regarding the manifestations
of Kabuki syndrome.
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